Wuxi Biologics

WuXi Biologics, a biotechnology research and development company headquartered in China, reported its most recent carbon emissions in 2025. In that year, the company's Scope 1 emissions were approximately 44.1 million kg CO2e, and its Scope 2 emissions were around 185.6 million kg CO2e. Key categories within Scope 3 emissions included fuel and energy-related activities at approximately 47.1 million kg CO2e, employee commute at about 22.5 million kg CO2e, and waste generated in operations at roughly 5.9 million kg CO2e. The company has not provided a total for its combined Scope 1, 2, and 3 emissions for 2025.

Looking back, in 2024, WuXi Biologics reported Scope 1 emissions of approximately 38.3 million kg CO2e and Scope 2 emissions of around 160.3 million kg CO2e. For Scope 3 in 2024, fuel and energy-related activities were about 39.5 million kg CO2e, employee commute was roughly 19.2 million kg CO2e, and waste generated in operations was approximately 5.9 million kg CO2e.

WuXi Biologics has set near-term Science Based Targets initiative (SBTi) commitments to reduce absolute Scope 1 and Scope 2 GHG emissions by 58.8% by 2034, using 2024 as the base year. Additionally, the company commits to reduce Scope 3 GHG emissions covering purchased goods and services by 63.8% per kg of product produced within the same timeframe. For the long term, WuXi Biologics aims to achieve net-zero greenhouse gas emissions across its value chain by 2050. This includes reducing absolute Scope 1 and Scope 2 GHG emissions by 90% by 2050 from a 2024 base year, and absolute Scope 3 GHG emissions from specific categories (purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and employee commuting) by 90% within the same timeframe.

The company also has a mid-term goal to reduce its Scope 1 and Scope 2 GHG emission intensity by 50% (tonnes/RMB10,000) by 2030, from a 2020 base year.